Neuropace
NPCE
48 hedge funds and large institutions have $103M invested in Neuropace in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 9 closing their positions.
800% more call options, than puts
Call options by funds: $9K | Put options by funds: $1K
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
0.51% more ownership
Funds ownership: 50.16% → 50.67% (+0.51%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $109M → $103M (-$5.97M)
6% less funds holding
Funds holding: 51 → 48 (-3)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.51M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$860K |
| 3 |
Millennium Management
New York
|
+$395K |
| 4 |
BlackRock
New York
|
+$248K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.77M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$478K |
| 3 |
Man Group
London,
United Kingdom
|
-$291K |
| 4 |
Two Sigma Investments
New York
|
-$250K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$246K |
NPCE Hedge Fund Activity: Q3 2024 in Review
48 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q3 2024, worth a combined $103M — down 5.5% from $109M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of NPCE and 7 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 17 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.51M. The largest seller was Deutsche Bank, cutting an estimated $1.77M.
- 48 institutional investors held Neuropace (NPCE) as of Q3 2024, down from 51 in Q2 2024.
- Funds reported $103M of Neuropace stock for Q3 2024, down 5.5% quarter-over-quarter.
- 7 funds opened new Neuropace positions in Q3 2024 and 9 closed out, a net change of -2 holders.
- The largest Neuropace buyer in Q3 2024 was Armistice Capital, an estimated $3.51M added.
- The largest Neuropace seller in Q3 2024 was Deutsche Bank, an estimated $1.77M sold.
Based on aggregated 13F filings for Q3 2024.